Subtopic Deep Dive
Malignant Pleural Mesothelioma
Research Guide
What is Malignant Pleural Mesothelioma?
Malignant Pleural Mesothelioma (MPM) is a rare, aggressive cancer of the pleural mesothelium strongly linked to asbestos exposure, particularly crocidolite.
MPM presents as diffuse pleural tumors with poor prognosis, primarily affecting individuals with occupational asbestos exposure. Wagner et al. (1960) first documented 33 cases tied to crocidolite in South Africa (1858 citations). Research spans epidemiology, pathogenesis via fiber retention, and surgical therapies like extrapleural pneumonectomy.
Why It Matters
MPM studies guide asbestos bans and occupational health policies worldwide, as Wagner et al. (1960) established the causal link driving regulations. Surgical outcomes from Sugarbaker et al. (1999, 979 citations) inform trimodality therapy, improving survival in 183 patients based on resection margins and nodal status. Donaldson et al. (2010, 866 citations) extend risks to carbon nanotubes, influencing nanomaterial safety standards.
Key Research Challenges
Heterogeneous Tumor Biology
MPM shows variable cell types and responses to therapy, complicating targeted treatments. Sugarbaker et al. (1999) found cell type and nodal status predict survival in 183 patients. Understanding pathogenesis remains key for novel therapies.
Long Latency from Exposure
Decades between asbestos exposure and MPM onset hinder epidemiological tracking. Wagner et al. (1960) reported cases 31-68 years old with prior crocidolite contact. This delays intervention and attribution in compensation claims.
Optimal Surgical Approach
Debate persists between extrapleural pneumonectomy and pleurectomy/decortication for survival. Flores et al. (2008, 605 citations) compared outcomes in 663 patients favoring less invasive options. Multimodal integration with chemotherapy challenges standardization.
Essential Papers
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. C. Wagner, C. A. Sleggs, P Marchand · 1960 · Occupational and Environmental Medicine · 1.9K citations
Primary malignant tumours of the pleura are uncommon. Thirty-three cases (22 males, 11 females, ages 31 to 68) of diffuse pleural mesothelioma are described; all but one have a probable exposure to...
The Role of CT Pulmonary Angiography in the Investigation of Unilateral Pleural Effusions
Clare Hooper, Isabel Laurence, John Harvey et al. · 2013 · Respiration · 1.2K citations
<b><i>Background:</i></b> Pulmonary embolism (PE) is frequently cited as a common primary cause of unilateral pleural effusion, but in clinical practice appears to be uncomm...
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
David J. Sugarbaker, Raja M. Flores, Michael T. Jaklitsch et al. · 1999 · Journal of Thoracic and Cardiovascular Surgery · 979 citations
Asbestos, carbon nanotubes and the pleural mesothelium: a review and the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma
Ken Donaldson, Fiona Murphy, Rodger Duffin et al. · 2010 · Particle and Fibre Toxicology · 866 citations
The unique hazard posed to the pleural mesothelium by asbestos has engendered concern in potential for a similar risk from high aspect ratio nanoparticles (HARN) such as carbon nanotubes. In the co...
Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube
Atsuya Takagi, Akihiko Hirose, Tetsuji Nishimura et al. · 2008 · The Journal of Toxicological Sciences · 815 citations
Nanomaterials of carbon origin tend to form various shapes of particles in micrometer dimensions. Among them, multi-wall carbon nanotubes (MWCNT) form fibrous or rod-shaped particles of length arou...
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
Tristan D. Yan, Marcello Deraco, Dario Baratti et al. · 2009 · Journal of Clinical Oncology · 675 citations
Purpose This multi-institutional registry study evaluated cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) for diffuse malignant peritoneal mesothelioma (...
Malignant mesothelioma
Bruce Robinson, Arthur W. Musk, Richard Lake · 2005 · The Lancet · 663 citations
Reading Guide
Foundational Papers
Start with Wagner et al. (1960, 1858 citations) for asbestos causation in 33 cases; then Sugarbaker et al. (1999, 979 citations) for trimodality survival factors in 183 patients.
Recent Advances
Study Donaldson et al. (2010, 866 citations) on nanotube pleural risks; Flores et al. (2008, 605 citations) comparing surgeries in 663 patients.
Core Methods
Core techniques: resection margin analysis (Sugarbaker 1999), fiber retention hypothesis (Donaldson 2010), MWCNT mouse models (Takagi 2008).
How PapersFlow Helps You Research Malignant Pleural Mesothelioma
Discover & Search
Research Agent uses searchPapers and citationGraph to map asbestos-MPM links from Wagner et al. (1960, 1858 citations), then findSimilarPapers uncovers Donaldson et al. (2010) on nanotubes.
Analyze & Verify
Analysis Agent applies readPaperContent to Sugarbaker et al. (1999), verifyResponse with CoVe checks survival stats, and runPythonAnalysis computes meta-survival rates across 183+ patients using GRADE for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in nanotube vs. asbestos mechanisms post-Donaldson (2010), while Writing Agent uses latexEditText, latexSyncCitations for surgical review papers, and latexCompile for formatted manuscripts with exportMermaid timelines.
Use Cases
"Run survival analysis on Sugarbaker 1999 MPM trimodality data"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas survival curves) → matplotlib plot of resection margin outcomes.
"Draft LaTeX review comparing EPP vs P/D in MPM surgery"
Synthesis Agent → gap detection (Flores 2008, Sugarbaker 1999) → Writing Agent → latexEditText + latexSyncCitations + latexCompile → PDF with citation graph.
"Find code for MWCNT mesothelioma mouse models"
Research Agent → paperExtractUrls (Takagi 2008) → Code Discovery → paperFindGithubRepo → githubRepoInspect → validated simulation scripts.
Automated Workflows
Deep Research workflow scans 50+ MPM papers via searchPapers, structures epidemiology reports from Wagner (1960) to Flores (2008). DeepScan applies 7-step CoVe to verify nanotube pathogenesis claims in Takagi et al. (2008). Theorizer generates hypotheses linking fiber length to inflammation from Donaldson (2010).
Frequently Asked Questions
What defines Malignant Pleural Mesothelioma?
MPM is an aggressive pleural cancer caused by asbestos, documented in 33 crocidolite-exposed cases by Wagner et al. (1960).
What are key methods in MPM research?
Methods include trimodality therapy (Sugarbaker 1999), surgical comparisons like EPP vs. P/D (Flores 2008), and animal models for MWCNT induction (Takagi 2008).
What are foundational MPM papers?
Wagner et al. (1960, 1858 citations) links asbestos to MPM; Sugarbaker et al. (1999, 979 citations) defines survival predictors.
What open problems exist in MPM?
Challenges include standardizing surgery (Flores 2008), extending asbestos risks to nanotubes (Donaldson 2010), and overcoming long latency for early detection.
Research Occupational and environmental lung diseases with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Malignant Pleural Mesothelioma with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers